Working… Menu
Trial record 100 of 332 for:    DONEPEZIL

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01276067
Recruitment Status : Completed
First Posted : January 13, 2011
Last Update Posted : July 20, 2012
Information provided by (Responsible Party):
Ranbaxy Inc. ( Ranbaxy Laboratories Limited )

Brief Summary:
This open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover study was conducted to compare the relative bioavailability of equal doses of the test and reference products under fasted conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Donepezil Phase 1

Detailed Description:

This open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover study was conducted to compare the relative bioavailability of equal doses of the test and reference products under fasted conditions. The study was conducted with 32 (31 completing) healthy adults in accordance with Protocol No. 10940307 (Revision 0). In each study period, a single 10 mg tablet of donepezil hydrochloride was administered to all subjects following an overnight fast of at least 10 hours. The test formulation was donepezil hydrochloride 10 mg tablet (OHM Laboratories, Inc., USA a subsidiary of Ranbaxy Pharmaceuticals, Inc. USA) and the reference formulation was ARICEPT® (donepezil hydrochloride) 10 mg Tablets (Eisai Inc.). The subjects received the test product in one study period and the reference product in the other period; the order of administration was according to the dosing randomization schedule. Subjects were confined at the clinical facility from at least 10 hours prior to dosing until after the 24 hour blood collection. Subjects returned to the clinical facility for the 36, 48, and 72 hour blood sample collection. There was a 28-day interval between treatments.

Blood samples were collected pre-dose and at intervals over 72 hours after dosing in each period. The plasma samples from all subjects were shipped to Warnex Bioanalytical Services for determination of donepezil concentrations.

Statistical analysis was performed by Ranbaxy Laboratories Limited to compare the bioequivalence of the test formulation to the reference product. Bioequivalence was determined based on the confidence intervals for the major pharmacokinetic parameters, AUC0-72 and Cmax, for donepezil.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Study to Evaluate the Relative Bioavailability of Donepezil Hydrochloride 10 mg Tablets (OHM Laboratories, Inc., USA) Compared to ARICEPT® (Donepezil Hydrochloride) 10 mg Tablets (Eisai Inc.) in Healthy Volunteers Under Fasted Conditions.
Study Start Date : October 2009
Actual Primary Completion Date : November 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
Drug: Donepezil
10 mg Tablet

Active Comparator: 2
ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
Drug: Donepezil
10 mg Tablet

Primary Outcome Measures :
  1. Bioequivalence evaluation of Donepezil 10mg tablets [ Time Frame: completed ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Males and females, 18 to 65 years of age (inclusive) and a Body Mass Index (BMI) 18 to 30 kg/m² inclusive. BMI will be calculated using Novum Pharmaceutical Research Services Standard Operating Procedures.
  2. Female subjects of child bearing potential must either abstain from sexual intercourse, or use a reliable non-hormonal method of contraception (e.g. condom with spermicide, IUD) for at least 30 days prior to dosing and during the duration of the study. The use of any type of hormonal contraception is not allowed
  3. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
  4. Signed and dated informed consent form, which meets all criteria of current FDA regulations.

Exclusion Criteria:

  1. Females who are pregnant, lactating or likely to become pregnant during the study.
  2. History of allergy or sensitivity to donepezil, other cholinesterase inhibitors, or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study
  3. Significant history or current evidence of chronic infectious disease, system disorder or organ dysfunction.
  4. Presence of gastrointestinal disease or history of malabsorption within the last year. Any history of gastrointestinal ulcers, bleeding or obstruction.
  5. History of asthma or obstructive pulmonary disease.
  6. History of psychiatric disorders occurring within the last two years that required hospitalization or medication.
  7. Presence of a medical condition requiring regular treatment with prescription drugs (including hormonal contraceptives).
  8. Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
  9. Receipt of any drug as part of a research study within 30 days prior to dosing.
  10. Drug or alcohol addiction requiring treatment in the past 12 months.
  11. Donation or significant loss of whole blood (480 ml or more) within 30 days or plasma within 14 days prior to dosing.
  12. Positive test results for HIV, Hepatitis B surface antigen or Hepatitis C antibody.
  13. Positive test results for drugs of abuse or alcohol at screening.
  14. Positive serum pregnancy test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01276067

Layout table for location information
United States, Pennsylvania
Novum Pharmaceutical Research Services
Pittsburgh,, Pennsylvania, United States
Sponsors and Collaborators
Ranbaxy Laboratories Limited

Additional Information:
Layout table for additonal information
Responsible Party: Ranbaxy Laboratories Limited Identifier: NCT01276067     History of Changes
Other Study ID Numbers: 10940307
First Posted: January 13, 2011    Key Record Dates
Last Update Posted: July 20, 2012
Last Verified: June 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents